NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development
This article was originally published in The Gray Sheet
Executive Summary
FDA Division of Clinical Laboratory Devices Director Steve Gutman is serving on a National Cancer Institute panel that will issue draft guidelines on cancer marker and assay development and publication of studies by early 2002
You may also be interested in...
Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29
Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29
Tissue Archiving May Preclude Prospective Data In Deciding Assay Utility
Drug companies anticipating use of molecular assays to complement therapies under development could be encouraged to rely on tissue-banked specimen analyses in lieu of prospective, randomized trials demonstrating clinical utility